/VIGL

VIGL Stock - Vigil Neuroscience, Inc.

Q: What is the analyst price target for VIGL?

Analyst price target information is not currently available for VIGL.

Q: What is VIGL's market cap?

Market capitalization information is not currently available for VIGL.

Healthcare|Biotechnology|NASDAQ

$8.05+0.00%

+$0.00 (+0.00%) • Aug 5

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-0.6%upside

Target: $8.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for VIGL

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta3.34

52W High$8.10

52W Low$1.31

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-453,000	$-399,000	$-1,010,000	$-345,000	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-89,683,000	$-88,866,000	$-68,884,000	$-42,409,000	$-6,291,000
Net Income	$-84,256,000	$-82,638,000	$-68,305,000	$-43,252,000	$-28,546,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-2.07	$-2.13	$-2.16	$-1.57	$-1.01

Company Overview

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

83%

Hold / Neutral

17%

Sell / Underperform

Analyst Consensus🟢 Bullish

5 Bullish1 Neutral/Bearish

Price Targets

$16

Average Target

↑ 92.5% Upside

Now

Low

$16

Average

$24

High

Based on 6 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
May 28th 2025	Stifel	Downgrade	Hold	$8
December 4th 2024	William Blair	Initiation	Outperform	-
December 19th 2023	Morgan Stanley	Downgrade	Underweight	$4← $13
October 18th 2023	JMP Securities	Initiation	Mkt Outperform	$23
March 31st 2023	Mizuho	Initiation	Buy	$15
September 16th 2022	Wedbush	Initiation	Outperform	$19
August 29th 2022	H.C. Wainwright	Initiation	Buy	$24

Earnings History & Surprises

VIGL

Beat Rate

73%

Last 15 quarters

Avg Surprise

+4.8%

EPS vs Estimate

Beats / Misses

11/4

Last 12 quarters

Latest EPS

$-0.56

Q3 2025

EPS Surprise History

Q4 23

+7.0%

$-0.53vs$-0.57

Q1 24

-1.8%

$-0.57vs$-0.56

Q2 24

+16.7%

$-0.50vs$-0.60

Q3 24

+3.7%

$-0.52vs$-0.54

Q4 24

+14.5%

$-0.47vs$-0.55

Q1 25

-16.3%

$-0.57vs$-0.49

Q2 25

+7.5%

$-0.49vs$-0.53

Q3 25

-30.2%

$-0.56vs$-0.43

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2025	Aug 5, 2025	$-0.43	$-0.56	-30.2%	✗ MISS
Q2 2025	May 7, 2025	$-0.53	$-0.49	+7.5%	✓ BEAT
Q1 2025	Mar 13, 2025	$-0.49	$-0.57	-16.3%	✗ MISS
Q4 2024	Nov 7, 2024	$-0.55	$-0.47	+14.5%	✓ BEAT
Q3 2024	Aug 13, 2024	$-0.54	$-0.52	+3.7%	✓ BEAT
Q2 2024	May 7, 2024	$-0.60	$-0.50	+16.7%	✓ BEAT
Q1 2024	Mar 26, 2024	$-0.56	$-0.57	-1.8%	✗ MISS
Q4 2023	Nov 7, 2023	$-0.57	$-0.53	+7.0%	✓ BEAT
Q3 2023	Aug 8, 2023	$-0.55	$-0.52	+5.5%	✓ BEAT
Q2 2023	May 10, 2023	$-0.53	$-0.51	+3.8%	✓ BEAT
Q1 2023	Mar 21, 2023	$-0.62	$-0.48	+22.6%	✓ BEAT
Q4 2022	Nov 10, 2022	$-0.59	$-0.53	+10.2%	✓ BEAT
Q3 2022	Aug 8, 2022	$-0.63	$-0.60	+4.8%	✓ BEAT
Q2 2022	May 12, 2022	$-0.55	$-0.58	-5.5%	✗ MISS
Q1 2022	Mar 25, 2022	$-0.65	$-0.46	+29.3%	✓ BEAT
Q1 2022	Jan 10, 2022	—	$-8.28	—	—
Q2 2021	Jun 30, 2021	—	$-0.54	—	—
Q1 2021	Mar 31, 2021	—	$-0.39	—	—
Q4 2020	Dec 31, 2020	—	$-0.20	—	—
Q3 2020	Sep 30, 2020	—	$-1.15	—	—

Frequently Asked Questions about VIGL

What is VIGL's current stock price?

Vigil Neuroscience, Inc. (VIGL) is currently trading at $8.05 per share. The stock has moved +0.00% today.

What is the analyst price target for VIGL?

The average analyst price target for VIGL is $8.00, based on 1 analyst.

What sector is Vigil Neuroscience, Inc. in?

Vigil Neuroscience, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is VIGL's market cap?

Vigil Neuroscience, Inc. has a market capitalization of $0.38 billion, making it a small-cap company.

Does VIGL pay dividends?

No, Vigil Neuroscience, Inc. does not currently pay a dividend to shareholders.